Anticancer

Diosmetin
Catalog No: CFN90210

Diosmetin has anti-osteoporosis, cytoprotective, antibacterial, anti-pigmentation, anti-inflammatory and antioxidant properties, it induces osteoblastic differentiation through the PKCδ-Rac1-MEK3/6-p38 and PKCδ-Rac1-MEK1/2- ERK1/2-Runx2 pathways.Diosmetin has intracellular antioxidant detoxifying effect, the mechanism is associated with both nonenzymatic and enzymatic defense systems.Diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.

Gamabufotalin
Catalog No: CFN90212

Gamabufotalin has been used for treatment of COX-2-mediated diseases and cancer therapy, it triggers c-Myc degradation via induction of WWP2 in multiple myeloma(MM) cells. Gamabufotalin strongly inhibit cancer cell growth and inflammatory response, it inhibits angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways and could be a potential candidate in angiogenesis-related disease therapy.

Aristolactam AIIIa
Catalog No: CFN97551

Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid.

1-O-Acetyl britannilactone
Catalog No: CFN90219

1-O-Acetyl britannilactone shows antifungal, and anti-cancer activities, it suppresses angiogenesis and lung cancer cell growth possibly via regulating the VEGFR-Src-FAK signaling. 1-O-Acetyl britannilactone may be one anti-inflammatory drug which inhibits the expression of COX-2 gene by blocking NF-κB activation and thus suppresses the inflammatory response to LPS in vascular smooth muscle cells.

Britannin
Catalog No: CFN90220

Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy.